Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459122 | 0.95 | POLB (0.54) | POLBGBA1HDAC8SLC22A1PRCP | |
| SCHEMBL23478106 | 0.90 | POLB (0.46) | POLBGBA1HDAC8SLC22A1PRCP | |
| SCHEMBL23477959 | 0.90 | POLB (0.46) | POLBGBA1HDAC8SLC22A1PRCP | |
| SCHEMBL25698301 | 0.80 | ALDH1A1 (0.49) | — | |
| SCHEMBL23477783 | 0.74 | POLB (0.57) | POLBGBA1LTA4H | |
| SCHEMBL23477826 | 0.72 | POLB (0.42) | POLBGBA1HDAC8SLC22A1PRCP | |
| SCHEMBL30428125 | 0.71 | POLB (0.41) | POLBGBA1HDAC8SLC22A1PRCP | |
| SCHEMBL25698481 | 0.70 | NOS3 (0.40) | POLBGBA1 | |
| SCHEMBL11766286 | 0.70 | KDM4E (0.47) | POLBSLC22A1 | |
| SCHEMBL23477892 | 0.70 | POLB (0.40) | POLBGBA1HDAC8SLC22A1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2021113506-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113506-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | POLB 260/4885GBA1 3258/4885HDAC8 732/4885 |
| US-20210188827-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | ATM, CHEK2, CHEK1 | POLB 260/4885GBA1 3258/4885HDAC8 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.